Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have been given a consensus rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $4.43.

ATRS has been the subject of a number of analyst reports. Vetr upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price objective for the company in a research report on Wednesday, July 5th. Chardan Capital initiated coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Antares Pharma in a research report on Friday, June 23rd. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Antares Pharma in a research report on Friday.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/09/antares-pharma-inc-atrs-given-average-recommendation-of-buy-by-brokerages.html.

Antares Pharma (ATRS) opened at 3.04 on Friday. The firm’s market capitalization is $475.48 million. Antares Pharma has a 12 month low of $1.27 and a 12 month high of $3.37. The stock has a 50 day moving average of $3.07 and a 200 day moving average of $2.88.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The company had revenue of $13.42 million during the quarter, compared to analyst estimates of $12.99 million. On average, equities analysts predict that Antares Pharma will post ($0.11) earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the business. Asymmetry Capital Management L.P. purchased a new position in shares of Antares Pharma during the second quarter worth approximately $643,000. California State Teachers Retirement System purchased a new position in shares of Antares Pharma during the second quarter worth approximately $820,000. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Antares Pharma during the second quarter worth approximately $307,000. The Manufacturers Life Insurance Company raised its stake in shares of Antares Pharma by 1,188.2% during the second quarter. The Manufacturers Life Insurance Company now owns 121,633 shares of the specialty pharmaceutical company’s stock worth $392,000 after acquiring an additional 112,191 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Antares Pharma during the second quarter worth approximately $174,000. 36.79% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.